Results 201 to 210 of about 569,399 (306)

Vitamin D‐induced mechanisms in cancer prevention and therapy: Recent advances and future opportunities

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Vitamin D, traditionally known to promote calcium and bone health, is being explored for its role in cancer prevention and treatment through its influence on cell proliferation, differentiation, apoptosis, and immune response. The vitamin D receptor (VDR) regulates gene expression and interacts with key signaling pathways such as Wnt/β‐catenin, MAPK ...
D. Prasanth   +10 more
wiley   +1 more source

Engineered Hydrogels Revolutionize Locoregional Cancer Immunotherapy

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review systematically summarizes the latest research progress on injectable hydrogels in cancer immunotherapy, highlighting their unique advantages in precise immune activation, local drug‐controlled release, and immune microenvironment remodeling. These features provide innovative solutions to overcome the bottlenecks of systemic side effects and
Jiyong Wei   +3 more
wiley   +1 more source

Metabolism‐Regulating Nanomedicines for Cancer Therapy

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

Low RYR2 Level Relates to Poor Prognosis of Patients With Lung Adenocarcinoma by Promoting Tumor Cell Proliferation and Inhibiting Immune Cell Infiltration

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Ryanodine receptor type 2 (RYR2) is a large calcium channel that has been identified as one of the most frequently mutated genes in lung adenocarcinoma (LUAD). Despite its potential significance, the role of RYR2 in LUAD remains poorly understood.
Tao Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy